オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - everolimus, quantity: 10 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; lactose monohydrate; hypromellose; magnesium stearate; crospovidone; lactose - everolimus sandoz is indicated for the treatment of:,? postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ? progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin. ? progressive, unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours (net) of gastrointestinal or lung origin in adults. ? advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib. ? subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection. ? patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - everolimus, quantity: 5 mg - tablet - excipient ingredients: butylated hydroxytoluene; hypromellose; lactose monohydrate; lactose; crospovidone; magnesium stearate - the treatment of: - postmenopausal women with hormone receptor-positive, her2 negative advanced breast cancer in combination with exemestane after failure of treatment with letrozole and anastrozole - progressive, unresectable or metastatic, well or moderately differentiated neuroendocrine tumours (nets) of pancreatic origin - advanced renal cell carcinoma after failure of treatment with sorafenib or sunitinib - subependymal giant cell astrocytoma (sega) associated with tuberous sclerosis complex (tsc) who require therapeutic intervention but are not candidates for curative surgical resection - patients with tuberous sclerosis complex (tsc) who have renal angiomyolipoma not requiring immediate surgery.

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - everolimus - oral tablet - 2.5mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - everolimus - oral tablet - 2.5mg

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

krka d.d. novo mesto d.d. - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

ベルギー - 英語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - everolimus 5 mg - tablet - 5 mg - everolimus 5 mg - everolimus

カナダ - 英語 - Health Canada

natco pharma (canada) inc - everolimus - tablet - 7.5mg - everolimus 7.5mg

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; crospovidone; ethanol absolute; hypromellose; lactose monohydrate; lactose; acetone; magnesium stearate - everolimus is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see section 4.4 special warnings and precautions for use).